Development System About SCGE | SCGE Toolkit The goal of the SCGE program is to accelerate the development of safer and more effective methods to edit the genomes of disease-relevant somatic cells and tissues in patients. For ethical, legal and safety reasons, the SCGE program does not support any research activities on genome editing in reproductive (germ) cells.
The SCGE Consortium is supported by the NIH Common Fund through cooperative agreements administered by the National Center for Advancing Translational Sciences, NIH Office of the Director, National Heart, Lung, and Blood Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Neurological Disorders and Stroke, National Institute of Allergy and Infectious Diseases, National Human Genome Research Institute, and National Institute of Biomedical Imaging and Bioengineering. The consortium is managed by a trans-NIH working group representing multiple NIH Institutes and Centers. For more information about the SCGE NIH Working Group and the Common Fund, please go here.
Select an Initiative below to browse studies submitted
Animal Reporting and Testing Centers
The initiative goal is to create and use new animal (mouse, pig, marmoset and rhesus macaque) reporter models to accelerate the translation of genome editing technologies into treatments for human diseases. The animal model systems are based on normal, non-diseased animals.
Genome Editor Projects
This initiative supports the development of innovative genome editing systems with improved specificity, efficiency or functionality over currently available systems, including the identification of complexes with novel enzymatic activities and substrate specificities.
Delivery Systems Initiative
The initiative goal is to support the development and evaluation of innovative approaches to deliver genome editing machinery into somatic cells, with the ultimate goal of accelerating the development of genome editing therapeutics to treat human disease. Funded projects are focusing on a wide array of disease-relevant cell types and testing multiple technologies for delivery to these cell types.
Biological Effects (Biological Systems)
The initiative goal is to support the development, validation and testing of new and existing human cell- and tissue-based platforms that can provide information on the safety of genome editing technologies and delivery systems. These models will be used for preclinical testing of editing, delivery and efficacy.
Biological Effects (In Vivo Cell Tracking Projects)
The objective of the program is to support the development of tools and technologies that will enable longitudinal monitoring and tracking of genome edited cells in humans to better assess the safety and efficacy of genome editing therapies. This will be accomplished through the development of innovative non-invasive technologies to label and track genome-edited cells in vivo, ideally in a clinically-relevant matter that has the potential to assess long-term safety in genome editing clinical trial participants.